Literature DB >> 12521358

Stimulation of the nervous system for the management of seizures: current and future developments.

Jerome V Murphy1, Arunangelo Patil.   

Abstract

Vagal nerve stimulation (VNS) for the treatment of refractory epilepsy appears to have started from the theory that since VNS can alter the EEG, it may influence epilepsy. It proved effective in several models of epilepsy and was then tried in short-term, open-label and double-blind trials, leading to approval in Canada, Europe and the US. Follow-up observations in these patients demonstrated continued improvement in seizure control for up to 2 years. Close to 50% of treated patients have achieved at least a 50% reduction in seizure frequency. This therapy was also useful as rescue therapy for ongoing seizures in some patients; many patients are more alert. The initial trials were completed in patients >/=12 years of age with refractory partial seizures. Subsequently, similar benefits were shown in patients with tuberous sclerosis complex, Lennox-Gastaut syndrome, hypothalamic hamartomas and primary generalised seizures. Implanting the generator and leads is technically easy, and complications are few. The method of action is largely unknown, although VNS appears to alter metabolic activity in specific brain nuclei. Considering that improvement in mood is frequently found in patients using VNS, it has undergone trials in patients with depression. Other illnesses deserving exploration with this unusual therapy are Alzheimer's disease and autism. Some aspects of VNS have proven disappointing. Although patients have fewer seizures, the number of antiepileptic drugs they take is not significantly reduced. In addition, there is no way to accurately predict the end of life of the generator. Optimal stimulation parameters, if they exist, are unknown. Deep brain stimulation is a new method for controlling medically refractory seizures. It is based on the observation that thalamic stimulation can influence the EEG over a wide area. Several thalamic nuclei have been the object of stimulation in different groups of patients. Intraoperative brain imaging is essential for electrode placement. The procedure is done under local anaesthesia. Experience with this therapy is currently limited, but growing.

Entities:  

Mesh:

Year:  2003        PMID: 12521358     DOI: 10.2165/00023210-200317020-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  74 in total

1.  Left vagus nerve stimulation with the neurocybernetic prosthesis has complex effects on heart rate and on its variability in humans.

Authors:  M G Frei; I Osorio
Journal:  Epilepsia       Date:  2001-08       Impact factor: 5.864

2.  Left vagal nerve stimulation in six patients with hypothalamic hamartomas.

Authors:  J V Murphy; J W Wheless; C M Schmoll
Journal:  Pediatr Neurol       Date:  2000-08       Impact factor: 3.372

3.  Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group.

Authors:  D Labar; J Murphy; E Tecoma
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

Review 4.  Vagus nerve stimulation therapy: a research update.

Authors:  Mark S George; Z Nahas; D E Bohning; F A Kozel; B Anderson; J-H Chae; M Lomarev; S Denslow; X Li; C Mu
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

5.  Some cerebellar influences on electrically-induced cerebral seizures.

Authors:  P M COOKE; R S SNIDER
Journal:  Epilepsia       Date:  1955-11       Impact factor: 5.864

6.  Preliminary evaluation of cerebellar stimulation by double-blind stimulation and biological criteria in the treatment of epilepsy.

Authors:  J M Van Buren; J H Wood; J Oakley; F Hambrecht
Journal:  J Neurosurg       Date:  1978-03       Impact factor: 5.115

7.  Therapeutic implications of modulation of metabolism and functional activity of cerebral cortex by chronic stimulation of cerebellum and thalamus.

Authors:  I S Cooper; A R Upton
Journal:  Biol Psychiatry       Date:  1985-07       Impact factor: 13.382

8.  Vagus nerve stimulator implantation in children.

Authors:  Daniel J Kirse; Andreas H Werle; Jerome V Murphy; Thomas P Eyen; Daniel E Bruegger; Gregory W Hornig; Richard D Torkelson
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-11

9.  Enhanced recognition memory following vagus nerve stimulation in human subjects.

Authors:  K B Clark; D K Naritoku; D C Smith; R A Browning; R A Jensen
Journal:  Nat Neurosci       Date:  1999-01       Impact factor: 24.884

10.  Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures.

Authors:  E Ben-Menachem; A Hamberger; T Hedner; E J Hammond; B M Uthman; J Slater; T Treig; H Stefan; R E Ramsay; J F Wernicke
Journal:  Epilepsy Res       Date:  1995-03       Impact factor: 3.045

View more
  5 in total

Review 1.  Theories of impaired consciousness in epilepsy.

Authors:  Lissa Yu; Hal Blumenfeld
Journal:  Ann N Y Acad Sci       Date:  2009-03       Impact factor: 5.691

2.  Bim regulation may determine hippocampal vulnerability after injurious seizures and in temporal lobe epilepsy.

Authors:  Sachiko Shinoda; Clara K Schindler; Robert Meller; Norman K So; Tomohiro Araki; Akitaka Yamamoto; Jing-Quan Lan; Waro Taki; Roger P Simon; David C Henshall
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  A new description of epileptic seizures based on dynamic analysis of a thalamocortical model.

Authors:  H Sohanian Haghighi; A H D Markazi
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

4.  Heart Rate Variability as a Prognostic Factor for Cancer Survival - A Systematic Review.

Authors:  Evelyne Kloter; Katja Barrueto; Sabine D Klein; Felix Scholkmann; Ursula Wolf
Journal:  Front Physiol       Date:  2018-05-29       Impact factor: 4.566

5.  Long-term seizure freedom following intracranial sEEG monitoring: Therapeutic benefit of a diagnostic technique.

Authors:  Manmeet Kaur; Jerzy P Szaflarski; Lawrence Ver Hoef; Sandipan Pati; Kristen O Riley; Zeenat Jaisani
Journal:  Epilepsy Behav Rep       Date:  2019-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.